NCT06793813View on ClinicalTrials.gov

Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Stage IVB Lung CancerNon-Squamous
Interventions
DRUG

cadonilimab，bevacizumab，docetaxel

Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

100000

RECRUITING

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER